WITHDRAWN—a resource for withdrawn and discontinued drugs
Open accessThe DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.
Abstract
Post-marketing drug withdrawals can be associated with various events, ranging from safety issues such as reported deaths or severe side-effects, to a multitude of non-safety problems including lack of efficacy, manufacturing, regulatory or business issues. During the last century, the majority of drugs voluntarily withdrawn from the market or prohibited by regulatory agencies was reported to be related to adverse drug reactions. Understanding the underlying mechanisms of toxicity is of utmost importance for current and future drug discovery. Here, we present WITHDRAWN, a resource for withdrawn and discontinued drugs publicly accessible at http://cheminfo.charite.de/withdrawn. Today, the database comprises 578 withdrawn or discontinued drugs, their structures, important physico-chemical properties, protein targets and relevant signaling pathways. A special focus of the database lies on the drugs withdrawn due to adverse reactions and toxic effects. For approximately one half of the drugs in the database, safety issues were identified as the main reason for withdrawal. Withdrawal reasons were extracted from the literature and manually classified into toxicity types representing adverse effects on different organs. A special feature of the database is the presence of multiple search options which will allow systematic analyses of withdrawn drugs and their mechanisms of toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most common toxicity types associated with drug withdrawals in the United States and Europe are hepatic (21%), cardiovascular (16%), hematological (11%), neurological (9%), and carcinogenicity (8%) (Figure 2) (20).”
From Limitations of Animal Studies for Predicting Toxicity in Clinical Trials (2019) · cites this paper as [20]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
KEGG: Kyoto Encyclopedia of Genes and Genomes
Kanehisa, M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.27 · Cited by 37,077
KEGG: Kyoto Encyclopedia of Genes and Genomes
Ogata, H., Goto, S., Sato, K., Fujibuchi, W., Bono, H., & Kanehisa, M. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.1.29 · Cited by 31,232
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
Predicting Functional Effect of Human Missense Mutations Using PolyPhen‐2
Adzhubei, I., Jordan, D. M., & Sunyaev, S. R. (2013) · Current Protocols in Human Genetics · doi:10.1002/0471142905.hg0720s76 · Cited by 3,705 · cited 1×
“Furthermore, the information on biological pathways and SNPs, including amino acid changes, peptide positions, MAFs, PolyPhen scores (37) and links to dbSNP, were added in the detailed record of a target.”
BackgroundData, information, knowledge and principle: back to metabolism in KEGG
Kanehisa, M., Goto, S., Sato, Y., Kawashima, M., Furumichi, M., & Tanabe, M. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1076 · Cited by 3,092
Adverse drug reactions: definitions, diagnosis, and management
Edwards, I. R., & Aronson, J. K. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02799-9 · Cited by 2,979
DrugBank: a knowledgebase for drugs, drug actions and drug targets
Wishart, D. S., Knox, C., Guo, A. C., Cheng, D., Shrivastava, S., Tzur, D., Gautam, B., & Hassanali, M. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkm958 · Cited by 2,861
An Algorithm for Subgraph Isomorphism
Ullmann, J. R. (1976) · Journal of the ACM · doi:10.1145/321921.321925 · Cited by 2,277
The ChEMBL bioactivity database: an update
Bento, A. P., Gaulton, A., Hersey, A., Bellis, L. J., Chambers, J., Davies, M., Krüger, F. A., Light, Y., Mak, L., McGlinchey, S., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1031 · Cited by 1,492
UniProt Knowledgebase: a hub of integrated protein data
Magrane, M., & Consortium, U. (2011) · Database · doi:10.1093/database/bar009 · Cited by 1,463
Cited by
Items 201–300 of 321
Zhang, Y., Liu, Y., Liu, W., & Chen, J. (2025) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5c00065 · Cited by 4
Comparison of Drug Withdrawal Processes in the U.S. and Other Nations
Patel, H., Wertheimer, A. I., & Ding, Q. (2021) · INNOVATIONS in pharmacy · doi:10.24926/iip.v12i3.3939 · Cited by 4
Zhang, H., Zhang, H.-R., Hu, M., & Qi, H.-Z. (2022) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2022.107185 · Cited by 4
Amrita, C., Kaur, I., Sharma, A. D., Sarkar, A., & Panja, A. S. (2024) · Chemical Papers · doi:10.1007/s11696-024-03786-8 · Cited by 4
FDA drug candidacy acceptance criteria and steps
Ezzat, S. M., Bishbishy, M. H. E., Walag, A. M. P., & Mtewa, A. G. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817890-4.00004-4 · Cited by 4
Ashenden, S. K., Deswal, S., Bulusu, K. C., Bartosik, A., & Shameer, K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820045-2.00004-0 · Cited by 4
QSAR models for predicting in vivo reproductive toxicity
Liu, J., Dong, F., Guo, W., Li, Z., Xu, L., Song, M., Patterson, T. A., & Hong, H. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-15339-6.00013-8 · Cited by 4
Postmarketing Surveillance of Drug-Induced Liver Injury
Jones, S. C., Kortepeter, C. M., & Brinker, A. D. (2018) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-7677-5_22 · Cited by 4
Rose, G., Pavlicek, A., & Gazsó, A. (2019) · doi:10.1553/ita-nt-050en · Cited by 4
Développement d'une plateforme de prédiction in silico des propriétés ADME-Tox
Canault, B. (2018) · theses.fr (ABES) · doi:10.70675/562e0758zcff7z49c4za806z3dded388daa0 · Cited by 4
Youssef, A., & Hammad, T. A. (2025) · Drug Safety · doi:10.1007/s40264-025-01640-8 · Cited by 3
Development of a CYP2D6-enhanced HepaRG cell model with improved CYP2D6 metabolic capacity
Obara, C., Iizaka, Y., Mine, A., Anzai, Y., Tada, M., & Yamaguchi, S. (2025) · PLoS ONE · doi:10.1371/journal.pone.0339559 · Cited by 3
Rana, P., Khan, S., Arat, S., Potter, D., & Khan, N. (2022) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.2c00243 · Cited by 3
Rejano, C. J. F., Tayo, L. L., Chen, B., & Tsai, P. (2023) · Letters in Drug Design & Discovery · doi:10.2174/0115701808268540231011071359 · Cited by 3
Bisht, T., Dhoundiyal, S., Adhikari, A., & Patil, S. R. (2023) · International Journal of Pharma Professional’s Research (IJPPR) · doi:10.48165/ijppronline.2023.14311 · Cited by 3
Mehnaj, Bhat, A. R., & Athar, F. (2024) · Medicinal Plant Biology · doi:10.48130/mpb-0024-0010 · Cited by 3
Kwofie, S. K., Asiedu, S. O., Koranteng, R., Quarshie, E., Tiburu, E. K., Miller, W. A., Adinortey, M. B., & Wilson, M. D. (2022) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2022.100957 · Cited by 3
Challenges and Opportunities in the Management of Cardiovascular Diseases
Sarma, H., Sahariah, J. J., Devi, R., & Sharma, H. K. (2022) · Sciences of Phytochemistry · doi:10.58920/sciphy01010042 · Cited by 3
Safety differentiation: emerging competitive edge in drug development
Uteng, M., Urbán, L., Brees, D., Muller, P. Y., Kullak-Ublick, G. A., Bouchard, P. R., Tougas, G. H., & Chibout, S. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.09.009 · Cited by 4
Rose, G., Pavlicek, A., & Gazsó, A. (2020) · doi:10.1553/ita-nt-050 · Cited by 3
Furtado, P. D. S., Viana, G. M., de Oliveira, A. A. S. C., Rabelo, V. W., Cerqueira, I. W., Paschoal, C. R. S., Honório, T. D. S., Simon, A., Rodrigues, C. R., Abreu, P. A., et al. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673262854231215065541 · Cited by 2
Saiyad, S. Y., Prajapati, A. N., Patel, T. S., Kataria, V. B., Dixit, B. C., & Dixit, R. B. (2024) · ChemistrySelect · doi:10.1002/slct.202402942 · Cited by 2
Sakatis, M. Z., Norona, L. M., Karmel, J., Proctor, W. R., Sarr, F. H., Rana, P., Zane, D., Rae, J. M. C., Faber, S. C., Ravindra, K. C., et al. (2025) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5c00235 · Cited by 2
Kiamehr, M., Manzini, S., Toprakhisar, B., da Costa, R. M., García-Llorens, G., Belay, B., Najimi, M., Castell, J. V., Moritz, W., Chiesa, G., et al. (2026) · Biofabrication · doi:10.1088/1758-5090/ae5fd8 · Cited by 2
Zhang, Y., Liu, Y., Xiao, Z., & Chen, J. (2026) · Environmental Science & Technology · doi:10.1021/acs.est.5c16775 · Cited by 2
Odame, F., Ayivor-Djanie, R., Madanhire, T., Mann, J., Neglo, D., Nanga, S., Hamenoo, E., Amengor, C. D. K., Acheampong, S., Biniyam, P. D., et al. (2026) · BioMed Research International · doi:10.1155/bmri/5076755 · Cited by 2
Okai, Y., Pfeiffer, E. R., Sameshima, T., Feric, N. T., Singh, R. K., Pallotta, I., Bogdanowicz, D. R., Gustilo, M. M., Harada, K., Baker, K. S., et al. (2025) · Toxicological Sciences · doi:10.1093/toxsci/kfaf033 · Cited by 2
Topological alternate centrality measure capturing drug targets in the network of MAPK pathways
Aksam, V. K. M., Chandrasekaran, V. M., & Pandurangan, S. (2018) · IET Systems Biology · doi:10.1049/iet-syb.2017.0058 · Cited by 2
Target identification and validation
Ashenden, S. K., Kurbatova, N., & Bartosik, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820045-2.00005-2 · Cited by 2
Arya, M., Tiwari, A., Singh, D. B., & Taj, G. (2023) · Letters in Drug Design & Discovery · doi:10.2174/1570180820666230224143303 · Cited by 2
(2023) · ARPN Journal of Engineering and Applied Sciences · doi:10.59018/0723195 · Cited by 2
Benko, A., & Webster, T. J. (2023) · Frontiers in Chemistry · doi:10.3389/fchem.2023.1267018 · Cited by 2
Investigating the association between CYP2J2 inhibitors and QT prolongation: a literature review
Wiley, A. M., Yang, J., Madhani, R., Nath, A., & Totah, R. A. (2024) · Drug Metabolism Reviews · doi:10.1080/03602532.2024.2329928 · Cited by 2
Cao, Y., Tian, G. G., Hong, X., Lü, Q., Wei, T., Chen, H., & Wu, J. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01261-1 · Cited by 2
Chuhan, A., & Sharma, A. D. (2024) · Ecological Frontiers · doi:10.1016/j.ecofro.2024.06.005 · Cited by 2
Evidence to Support Inclusion of Pharmacogenetic Biomarkers in Randomised Controlled Trials
Johnson, D., Hughes, D. A., Pirmohamed, M., & Jorgensen, A. (2019) · Journal of Personalized Medicine · doi:10.3390/jpm9030042 · Cited by 2
Self-Standing Photo-Crosslinked Hydrogel Construct: in vitro Microphysiological Vascular Model
Manigandan, A., Ramesh, P. A., Sethuraman, S., & Subramanian, A. (2021) · Cells Tissues Organs · doi:10.1159/000514986 · Cited by 2
Chipiso, K., & Simoyi, R. H. (2017) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.7b07404 · Cited by 1
Hamdi, S., Aydi, R., Dhouib, I., Jlidi, M., Abdmouleh, F., Maalej, A., Arbi, M. E., Chamkha, M., & Kammoun, M. (2024) · Chemistry Africa · doi:10.1007/s42250-024-00903-8 · Cited by 1
Vanisri., M., Sreesivasakthi, A., MuthuKaviya., M., Jayashankar, R., Salai Dhivyathai., N., Rajaganapathy, K., & Srinivasan.R (2024) · International Journal of Science and Research Archive · doi:10.30574/ijsra.2024.12.2.1197 · Cited by 1
Daniellia oliveri as a type 2 diabetes remedy: evidence from in-silico evaluation
Adeyemi, S. B., Saliu, A. A., Joshi, B., & Krishnamurthy, R. (2024) · Egyptian Journal of Basic and Applied Sciences · doi:10.1080/2314808x.2024.2434995 · Cited by 1
Kannan, S., Hammamieh, R., & Chakraborty, N. (2025) · Methods in molecular biology · doi:10.1007/978-1-0716-4276-4_17 · Cited by 1
Rahman, M. O., Saha, S. R., Abdullah, M. S., Hasan, M. M., Protiva, A. A., Siddique, I. H., Uzzaman, M., & Akter, B. (2025) · Monatshefte für Chemie - Chemical Monthly · doi:10.1007/s00706-025-03401-w · Cited by 1
Subspace-constrained graph unlearning for forgetting high-risk compound-protein interactions
Zhang, Y., Hu, R., Li, Y., & Kang, Z. (2025) · Knowledge-Based Systems · doi:10.1016/j.knosys.2025.115193 · Cited by 1
Chauhan, A., Sharma, A. D., Kaur, I., Panja, A. S., & Alam, S. A. (2026) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.70178 · Cited by 1
In Silico ADMET: From Current Practices to Novel Profilers
Llompart, P., Minoletti, C., Marcou, G., & Varnek, A. A. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00049 · Cited by 1
X-DILiver: an ensemble learning framework for predicting drug-induced liver injury
Lee, J., Yu, M., Lee, Y. L., Nam, H. J., Oh, K., Jang, J., Lee, H.-M., & Na, D. (2026) · Scientific Reports · doi:10.1038/s41598-026-59299-9 · Cited by 1
In Vitro Cardiotoxicity Investigation Using High Content Analysis and Human Stem Cell-Derived Models
Roquemore, L., Kauss, M. A., Hather, C., Thomas, N., & Uppal, H. (2016) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-6661-5_13 · Cited by 1
Parliament in action: Drug withdrawals and policy changes in the U.K.
Zec, D. N., Rüling, C.-C., & Wang, T. (2020) · Health Policy · doi:10.1016/j.healthpol.2020.07.005 · Cited by 1
Brito, S. J. V., Rodríguez-Hernández, A. G., Viña, L., & Rodríguez, Y. (2021) · Lecture notes in networks and systems · doi:10.1007/978-3-030-74608-7_13 · Cited by 1
Tools and Techniques to Tap the Potential of Himalayan Bioactive Molecules
Shagun, S., & Masakapalli, S. K. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815123289123010014 · Cited by 1
Babalola, S., Hayatuddeen, M. Y., Yunusa, I. A., & Asmau, H. N. (2023) · Drug Discovery · doi:10.54905/disssi.v17i39.e25dd1935 · Cited by 1
Frimayanti, N., Febrina, M., & Amalia, A. Y. (2024) · Jurnal Riset Kimia · doi:10.25077/jrk.v15i1.638 · Cited by 1
In-silico Docking and ADMET: Recent Innovations of Carvone
Srivastava, S., Sinha, R., Lavhale, P. M., & Kurmi, R. K. (2023) · INTERNATIONAL JOURNAL OF PHARMACEUTICAL EDUCATION AND RESEARCH (IJPER) · doi:10.37021/ijper.v5i1.02 · Cited by 1
Gunwhy, E. R., Hines, C. D. G., Green, C., Laitinen, I., Tadimalla, S., Hockings, P. D., Schütz, G., Kenna, J. G., Sourbron, S. P., & Waterton, J. C. (2024) · Magnetic Resonance Materials in Physics Biology and Medicine · doi:10.1007/s10334-024-01192-5 · Cited by 1
Target identification and validation in drug discovery
Chakraborty, S., Ghosh, R., Rakshit, G., Singh, N. K., & Rudrapal, M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27461-9.00005-6 · Cited by 1
Che Roos, N. A. (2019) · Enlighten: Theses (The University of Glasgow) · doi:10.5525/gla.thesis.41064 · Cited by 1
Okombo, O. J. (2018) · Open University of Cape Town (University of Cape Town) · Cited by 1
Product recalls, market size and innovation in the pharmaceutical industryPreprint
Nutarelli, F., Riccaboni, M., & Morescalchi, A. (2021) · RePEc: Research Papers in Economics · doi:10.48550/arxiv.2111.15389 · Cited by 1
Revista Electronica de Veterinaria
Banwala, S., Sardana, S., & Sindhu, R. K. (2024) · doi:10.53555//redvet.v25i1.601 · Cited by 1
At the intersection between Machine Learning and Econometrics: theory and applications
Nutarelli, F. (2022) · doi:10.13118/imtlucca/e-theses/346 · Cited by 1
Conception d'un logiciel pour la recherche de nouvelles molécules bioactives
Bournez, C. (2019) · theses.fr (ABES) · doi:10.70675/1a4f06f0zdfa4z41efza87az70239c45c50c · Cited by 2
Nickel-Seeber, J. (2017) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-16305
Onakpoya, I. (2017) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-jvvmg2e9g
Cheminformatics Approaches to Drug Discovery
Siramshetty, V. B. (2019) · doi:10.17169/refubium-2298
Self-citationEffect of Bezafibrate on Deoxyribonucleic Acid in the Presence of Iron and Copper
Arman, İ. (2019) · Turkish Journal of Diabetes and Obesity · doi:10.25048/tjdo.2019.49
Qi, Z., Kamoshida, M., Tamai, M., Hirose, M., & Tagawa, Y. (2020) · Translational and Regulatory Sciences · doi:10.33611/trs.2_7
Targeting influenza at the Topologically conserved substructures
Ahamed, Z., Kamjula, V., & Bhuvaneswari, K. (2021) · Asian Journal of Pharmacy and Technology · doi:10.52711/2231-5713.2021.00020
O papel da farmacogenómica na investigação clínica
Carvalho, I. S. D. C. (2019) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Endbericht SafeNanoKap Round Tables 18.10. & 22.11.2017
Gazsó, A., Pavlicek, A., & Rose, G. (2018) · doi:10.1553/ita-pb-2018-02
Riyadi, P. H., Khayati, N., Silsilia, M. D., Surya, R. A., Aryanti, S. S., & Mulyadi, S. A. (2022) · SAINTEK PERIKANAN Indonesian Journal of Fisheries Science and Technology · doi:10.14710/ijfst.18.2.105-112
Cho, W.-W., Park, W., Cho, D., & Yi, H. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-823536-2.00003-1
Yoon, J., Syafiandini, A. F., & Song, M. (2023) · Journal of Informetrics · doi:10.1016/j.joi.2023.101412
DNA Binding Effect and Antibacterial Effect of Bezafibrate, an Antilipemic Agent
Arman, İ. (2020) · Advances in Pharmacology & Clinical Trials · doi:10.23880/apct-16000176
Bioengineering hepatic organoids: Development of an alternative model for liver toxicity
Bouwmeester, M. (2023) · Utrecht University Repository (Utrecht University) · doi:10.33540/2054
Afreen, U., Afreen, U., & Bano, D. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815196986123010006
Eulogy for B&O Suppositories: A Resident’s Remembrance of Rectal Relief
Grimaud, L., & Peterson, A. C. (2024) · Urology · doi:10.1016/j.urology.2024.04.044
Respiratory Function as a Safety Concern in Drug Development
Bouchard, A., & Salvail, D. (2024) · Springer eBooks · doi:10.1007/978-3-030-73317-9_65-1
Respiratory Function as a Safety Concern in Drug Development
Bouchard, A., & Salvail, D. (2024) · Springer eBooks · doi:10.1007/978-3-031-35529-5_65
Sharma, A. D., & Chauhan, A. (2024) · Discover Plants. · doi:10.1007/s44372-024-00040-z
Case Study #6: Building a Kidney-Chip to Improve Drug Development and Nephrotoxicity Predictions
Jeanty, S. S. F., & Sliz, J. D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-95680-2.00005-3
Fiscalização sanitária de medicamentos na instância federal: organização e condições de trabalho
Martins, M. A. F., Scherer, M. D. D. A., & Gomes, R. F. D. O. (2025) · Vigilância Sanitária em Debate · doi:10.22239/2317-269x.02355
Slotvitsky, М. М., Romanova, S. A., Dabizha, M. O., Al-Khateeb, R. A., Игоревич, А. К., & Tsvelaya, V. A. (2025) · Biochemistry (Moscow) Supplement Series A Membrane and Cell Biology · doi:10.1134/s1990747825700187
Bitam, S., Hamadache, M., & Hanini, S. (2025) · In Silico Pharmacology · doi:10.1007/s40203-025-00482-7
Gu, Y., Wang, Y., Zhu, K., Li, W., Liu, G., & Tang, Y. (2024) · Figshare · doi:10.6084/m9.figshare.24953278
Gu, Y., Wang, Y., Zhu, K., Li, W., Liu, G., & Tang, Y. (2024) · Figshare · doi:10.6084/m9.figshare.24953129
Additional file 1 of ProfhEX: AI-based platform for small molecules liability profiling
Lunghini, F., Fava, A., Pisapia, V., Sacco, F., Iaconis, D., & Beccari, A. R. (2024) · Figshare · doi:10.6084/m9.figshare.26596124
The Drug Health Surveillance Process in the Federal Regulatory Authority
Martins, M. A. F. (2022) · RIUnB Institutional Repository (University of Brasília)
Mohamed, A. K. (2021) · Durham e-Theses (Durham University)
Frimayanti, N., Fernando, A., Rahmah, R. I., & Iskandar, B. (2026) · CHEMPUBLISH JOURNAL · doi:10.22437/chp.v9i2.43598
3 Rs: Repurposing and Reformulation of Therapeutics
Kumari, M., Dwivedi, M., Pandey, A., & Chaurasia, S. (2026) · Springer eBooks · doi:10.1007/978-981-95-4522-3_9
Dutta, S., & Mitra, P. (2026) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2026.100223
Abdullahi, A. S., Ayoola, G. A., Orojuekun, D. B., Adeyemi, D. K., Johnson, O. O., Ishola, I. O., Adeluola, A. O., & Ologunagba, M. O. (2026) · Research Square · doi:10.21203/rs.3.rs-8941887/v1
Lee, S., Jin, C., Choi, H., & Kim, J. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00724
Xin, L., Zhang, Y., Liu, X., Liang, R., Ma, R., Wang, Y., & Cui, P. (2026) · Molecular Diversity · doi:10.1007/s11030-026-11500-x
Evaluation of reflection of chirality to drug safety and cost
Bahar, A. (2021) · Dspace Repository (Marmara Üniversitesi)
Jee, A. (2024) · TSpace (University of Toronto)
Sun, H., Li, L., Kim, E., Lee, B.-K., & Lee, D. (2026) · IEEE International Conference on Micro Electro Mechanical Systems (MEMS) · doi:10.1109/mems64181.2026.11419567
Metadata
- Authors
- Siramshetty, V. B., Nickel, J., Omieczynski, C., Gohlke, B.-O., Drwal, M. N., & Preissner, R.
- Affiliations
- Charité – Universitätsmedizin Berlin (DE)
- German Cancer Research Center (DE)
- Corresponding author
- Drwal, Malgorzata N.
- Preissner, Robert
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-11-08
- Volume
- 44
- Issue
- D1
- Pages
- D1080-D1086
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- PMC
- PMC4702851
- OpenAlex
- W2147670638
- Cited by
- 286
- References
- 45
- Citations by year
- 2026: 21 · 2025: 23 · 2024: 35 · 2023: 36 · 2022: 27 · 2021: 28 · 2020: 37 · 2019: 24 · 2018: 30 · 2017: 12 · 2016: 12 · 2015: 1
- FWCI
- 14.82
- Type
- journal article
- Language
- en
- Status
- Retracted
- Open access
- gold
- doi.org
- Licence
- Locations
- Nucleic Acids Research (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (acceptedVersion)
- HighWire Press Open Archive (submittedVersion)
- Refubium (Universitätsbibliothek der Freien Universität Berlin) (submittedVersion, cc-by-nc)
- Funders
- Bundesministerium für Bildung und Forschung
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Health Informatics › Biomedical Text Mining and Ontologies
- Keywords
- drug withdrawal, adverse drug reactions, drug toxicity, toxicity mechanisms, drug safety, drug discovery, chemical databases, protein targets, signaling pathways, physicochemical properties
- MeSH terms
- Pharmaceutical Preparations, Humans, Proteins, Signal Transduction, Internet, Polymorphism, Single Nucleotide, Drug Recalls, Safety-Based Drug Withdrawals, Databases, Pharmaceutical, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.